Attaya Suvannasankha

10PUBLICATIONS
66CO-AUTHORS
Gene and molecular therapyPredictive and prognostic markersMedical molecular engineering of nucleic acids and proteinsHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jul 29, 2026
SGLT-2 Inhibitors are Associated With a Lower Risk of Multiple Myeloma.

|Jun 12, 2026
Second Primary Malignancy Risk in Patients with Multiple Myeloma Receiving CAR T-Cell Therapy or Other Systemic Anticancer Treatments: A Real-World Comparative Study.

|Oct 15, 2025
Diagnostic sequencing identifies high-risk markers and mechanisms of resistance to guide immunotherapy selection.

Parvathi Sudha, Phillip Pham, Wen Niu

|May 08, 2025
Identification of the Distinct Immune Microenvironment Features Associated with Progression Following High-Dose Melphalan and Autologous Stem Cell Transplant in Multiple Myeloma.

Parvathi Sudha, Travis S Johnson, Habib Hamidi

|Jun 16, 2024
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.

Naresh Bumma, Joshua Richter, Sundar Jagannath

|May 16, 2024
1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma.

Travis S Johnson, Parvathi Sudha, Enze Liu

Pageof 2

Frequent Collaborators

5 joint publications

Brian A Walker

3 joint publications

Enze Liu

3 joint publications

Gareth Morgan

3 joint publications

Parvathi Sudha